How many outstanding shares does AstraZeneca have?
How many shares does AstraZeneca have outstanding? The total number of shares in issue as at 31 December 2021 was 1,549,400,665. AstraZeneca PLC publishes its total number of voting rights each month. These notifications can be found in the Stock exchange announcements.
Is AZN a good stock to buy now?
AstraZeneca PLC – Hold Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of AZN, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
Who owns the most shares in AstraZeneca?
Top 10 Owners of AstraZeneca PLC
|T. Rowe Price Associates, Inc. (I…||2.90%||89,840,751|
|Wellington Management Co. LLP||1.52%||47,105,051|
|PRIMECAP Management Co.||1.51%||46,690,500|
|Capital Research & Management Co….||1.14%||35,388,789|
What is AstraZeneca share price in pounds sterling?
AstraZeneca Market Data
Who is the largest shareholder of Google?
Top 10 Owners of Alphabet Inc
|The Vanguard Group, Inc.||7.23%||21,730,813|
|BlackRock Fund Advisors||4.37%||13,143,261|
|Fidelity Management & Research Co…||4.12%||12,400,244|
|SSgA Funds Management, Inc.||3.74%||11,252,792|
Who owns the controlling interest in AstraZeneca?
AstraZeneca is not owned by hedge funds. BlackRock, Inc. is currently the largest shareholder, with 8.4% of shares outstanding. For context, the second largest shareholder holds about 7.1% of the shares outstanding, followed by an ownership of 5.8% by the third-largest shareholder.
Why is AstraZeneca share price going down?
The pharmaceutical giant’s stock AZN, +0.71% AZN, -0.55% slid more than 4% after it announced a net loss for the third quarter, despite a jump in revenue, due to costs of developing its COVID vaccine.
Why have AstraZeneca shares gone up?
AstraZeneca shares rise after signing global drug deal Shares in pharmaceutical giant AstraZeneca (AZN) gained 0.9% to £86.85 after the company sealed a commercialization agreement with Ionis Pharmaceuticals for the development and sale of eplonsteren which is in late stage trials.